bristol-myers squibb - Search News

News

BioNTech, Bristol Myers Squibb and cancer immunotherapy

Reuters on MSN · 3d

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

Bristol Myers Squibb, BioNTech partner on $11B cancer drug deal

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Bloomberg · 3d

Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors.

Fierce Pharma2d

ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the ...

3don MSN

Why BioNTech Stock Soared Today

Bristol Myers Squibb just agreed to shower BioNTech with cash. BioNTech ( BNTX 20.01%), one of the companies made famous for ...

Barchart on MSN1d

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company. With a market cap of ...

3d

Trump's steel tariffs, Bristol Myers-BioNTech, sports bet tax

Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including ...

Biontech trades half of bispecific BNT-327 to BMS for potential $11B+

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...

3d

BioNTech-Aktie steigt - Bristol zahlt bis zu $11,1 Mrd. in Krebsmedikament-Deal

Bristol-Myers Squibb wird BioNTech bis zu 11,1 Milliarden Dollar (9,7 Milliarden Euro) für die Lizenzierung eines ...

Plant Services3d

Factory fallout: Manufacturing plant closures and layoffs from Jeld-Wen, Bristol Myers Squibb, Wabash, and more

Companies are navigating a delicate balance between cost-cutting and staying ahead in a changing manufacturing economy.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results